A groundbreaking clinical trial has provided the first real-world evidence that an interactive, game-based technology can train individuals to modulate their own brain waves, offering a potential paradigm shift in the management of chronic nerve pain. Developed by a dedicated team of researchers at UNSW Sydney, the technology—known as "PainWaive"—is designed to help patients regulate abnormal brain activity associated with neuropathic pain. By providing a non-invasive, in-home alternative to traditional pharmacological interventions, this innovation could eventually offer a powerful, drug-free tool to those currently reliant on opioids.
The results of the initial study, led by Professor Sylvia Gustin and Dr. Negin Hesam-Shariati from the NeuroRecovery Research Hub at UNSW Sydney, were recently published in the Journal of Pain. This pilot study marks a significant milestone in neuro-rehabilitation, as it moves beyond theoretical research into practical, patient-centered application.
The trial involved a cohort of participants who underwent four weeks of intensive interactive gameplay. Throughout this period, researchers meticulously tracked hundreds of metrics related to pain intensity and pain interference, measuring the patients’ status before, during, and after the intervention. To monitor progress, participants wore specialized EEG (electroencephalogram) headsets. These devices were not merely passive recorders; they functioned as the interface for the app, which provided real-time feedback by responding instantly to shifts in the users’ brainwave patterns.
The clinical outcomes were striking. Three out of the four participants involved in the trial reported significant reductions in their chronic pain, with the most pronounced improvements appearing as they neared the conclusion of the four-week regimen. Perhaps most impressively, the level of pain relief achieved by these participants was found to be comparable to, or in some cases even greater than, the relief typically provided by opioid-based treatments.
While these findings are undeniably positive, the research team remains appropriately cautious, emphasizing the necessity of further investigation. "Restrictions in the study’s size, design and duration limit our ability to generalise the findings or rule out placebo effects," acknowledges Dr. Hesam-Shariati. Nevertheless, she notes that the data has provided the team with the necessary confidence to advance the technology toward larger, more comprehensive clinical trials.
The foundation of the PainWaive project is rooted in the extensive, years-long research conducted by Professor Gustin, who has focused on the specific neurological changes that occur within the thalamus—a critical relay station in the brain—in patients suffering from neuropathic pain. Through her work, Professor Gustin identified that the brainwaves of individuals living with nerve pain exhibit a distinct, pathological signature.
"The brainwaves of people with neuropathic pain show a distinct pattern: more slow theta waves, fewer alpha waves, and more fast, high beta waves," Professor Gustin explains. The hypothesis is that these aberrant electrical rhythms disrupt the vital communication channels between the thalamus and the sensory motor cortex, which is the region of the brain responsible for registering and processing pain signals. The core question driving the research team was simple yet ambitious: Could they develop a therapeutic intervention that could directly target and normalize these dysfunctional brain waves?
The task of translating this hypothesis into a functional tool fell to an interdisciplinary team of scientists from UNSW Science and Neuroscience Research Australia (NeuRA). The resulting technology, PainWaive, was engineered to provide patients with an accessible, at-home solution.
In the initial trial, participants were provided with a comprehensive "pain management kit," which included a bespoke EEG headset and a tablet pre-loaded with the PainWaive game app. The app included clear, structured directions on how to engage with the software. Beyond the game itself, participants were taught specific mental strategies—such as deep relaxation techniques or the deliberate focus on positive, happy memories—to help them exert voluntary control over their neural state and steer their brain activity toward a more "normal" range. Throughout the process, the raw data generated by the headset was uploaded to the research team, allowing them to provide remote monitoring and support.
The user experience was designed to minimize the need for clinical supervision. "After just a couple of Zoom sessions, participants were able to run the treatment entirely on their own," says Dr. Hesam-Shariati. This independence is a cornerstone of the project’s design philosophy. By shifting the power of pain management from the clinic to the home, the researchers believe they are addressing a fundamental need for autonomy among patients suffering from long-term, debilitating conditions. "Participants felt empowered to manage their pain in their own environment. That’s a huge part of what makes this special," she adds.
The journey to creating a hardware system that was both affordable and high-performing was not without its hurdles. Dr. Hesam-Shariati notes that the team initially explored the possibility of using commercially available EEG systems. However, they quickly discovered that existing consumer-grade technology lacked the precision required for clinical neuro-modulation, while professional-grade equipment was prohibitively expensive.
Driven by necessity, the team chose to build their own hardware from the ground up. "Everything except the open-source EEG board was built in-house," explains Dr. Hesam-Shariati, adding that they are already working toward replacing even that component with a custom-designed board. By utilizing 3D printing technology, the team has managed to reduce the cost of producing each headset to approximately $300. This is a dramatic departure from the $1,000 to $20,000 price tags typically associated with clinical EEG systems, a disparity that often creates a barrier to entry for many patients.
The headset itself is engineered for comfort and efficacy, utilizing a saline-based wet electrode system that significantly improves signal quality when targeting the sensorimotor cortex. "We’ve worked closely with patients to ensure the headset is lightweight, comfortable, and user-friendly," says Professor Gustin. The ultimate objective is to transform PainWaive into a widely accessible solution that democratizes pain management, particularly for those who currently have limited or no access to traditional pain clinics or specialized treatments.
As the research moves forward, the team at UNSW is scaling up its efforts to validate the technology across broader populations. They have officially issued a call for participants to register their interest in two upcoming major trials. The first, titled the "Spinal Pain Trial," aims to investigate the efficacy of the neuromodulation technology in reducing chronic spinal pain. The second, the "StoPain Trial," will focus on the use of PainWaive in treating chronic neuropathic pain specifically among individuals who have suffered a spinal cord injury.
These upcoming trials represent the next critical phase in determining whether PainWaive can transition from a promising pilot study to a standard-of-care, non-pharmacological treatment. By continuing to refine both the hardware and the mental strategies used to influence brain activity, the researchers hope to offer a durable, long-term solution for patients who have spent years navigating the limitations and side effects of conventional medicine. As the field of neuro-rehabilitation continues to evolve, the success of this project could signify a future where patients no longer rely on external chemical interventions, but instead harness the inherent plasticity of their own brains to silence the signals of chronic pain.
